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Objective. In rheumatoid arthritis (RA), autoreactive B cells are pathogenic drivers and sources of anticitrullinated protein antibodies (ACPAs) that are a diagnostic biomarker and predictor of worse long-term prognosis. Yet, the immunobiologic significance of persistent ACPA production at the cellular level is poorly understood. This study was undertaken to investigate the representation of ACPA-expressing switched-memory B cells in RA.
Methods. In a cross-sectional study of RA patients, we investigated the presence of continued defects in immune homeostasis as a function of disease activity. Using an enzyme-linked immunosorbent assay (ELISA) and a sensitive multiplex bead-based immunoassay, we characterized fine binding antibody specificities in sera, synovial fluid (SF), and B cell culture supernatants. In this manner, we determined the frequency and epitope reactivity patterns of ACPAs produced by SF B cells and switched-memory blood B cells and compared the latter to serum ACPA levels and disease activity scores.
Results. Cultured B cells from SF were shown to spontaneously secrete ACPAs, while constitutive IgG autoantibody production by peripheral blood mononuclear cells (PBMCs) was substantially less frequent. After in vitro stimulation, PBMCs secreted IgG ACPA that was overwhelmingly from switched-memory B cells, across all patient groups treated with methotrexate and/or a tumor necrosis factor inhibitor. Intriguingly, the frequencies of ACPA-expressing switched-memory B cells significantly correlated with serum IgG anti-cyclic citrullinated peptide 3 (r 5 0.57, P 5 0.003). Moreover, treatment-induced clinical remission had little or no effect on the circulating burden of switched-memory ACPA-expressing B cells, in part explaining the continued dysregulation of humoral immunity.
Conclusion. Our findings rationalize why therapeutic cessation most often results in disease reactivation and clinical flare. Hence, a clinical disease activity score is not a reliable indicator of the resolution of pathologic recirculating B cell autoimmunity.
Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting ;1-2% of Western populations that can lead to joint destruction, disability, and early mortality (1, 2) . Disease is postulated to be initiated by an inflammatory response in periodontal tissue, pulmonary airways, and/or the intestine (3) (4) (5) (6) . Progression to tissue injury is linked to a specific breach in immunologic tolerance to autoantigens generated by a posttranslational enzymatic process, citrullination, that modifies the side chains of arginine residues. In fact, circulating anti-citrullinated protein antibodies (ACPAs), which recognize a progressively expanding number of citrullinated protein epitopes, may arise years before symptomatic joint involvement (7, 8) . ACPAs themselves and ACPAcontaining immune complexes have been postulated to be directly pathogenic (9) . Moreover, B lymphocytes, which infiltrate the inflamed synovial membranes of affected joints and locally produce ACPAs and rheumatoid factor (RF), also contribute to pathogenesis through antigen presentation, costimulation of CD41 T cells, and secretion of chemokines and cytokines such as interleukin-6 (IL-6), tumor necrosis factor (TNF), and RANKL (10) (11) (12) (13) .
The presence of serum ACPAs, as detected by a cyclic citrullinated peptide (CCP) assay, both serves as a diagnostic biomarker and predicts a worse prognosis for progressive joint damage (14) . At clinical onset, RA patients also have expansions of memory B cell subset(s) that correlate with worse long-term clinical outcomes (15) . Importantly, even though treat-to-target strategies can more dependably induce low disease activity and clinical remission, serum ACPAs nonetheless generally persist. The immunobiologic basis for this persistence remains obscure, since ACPA production in ectopic synovial lymphoid tissue is presumably diminished with disease remission. It can be postulated that ACPAs continue to be spontaneously produced by long-lived plasma cells in the bone marrow or other sites, which have become disconnected from a previous pathogenic synovial process. We decided to test this model by determining whether disease-associated autoreactive peripheral B cells disappeared or persisted in patients in treatment-induced clinical remission.
Herein, we have compared the binding specificities of serum antibodies and peripheral blood B cells, with special focus on the representation of ACPA-expressing switched-memory B cells, which require additional stimuli to secrete antibodies. We have also characterized the fine binding specificities of these memory B cells, and enumerated their frequencies in the peripheral blood. Importantly, to better understand the effect of treatment on the underlying autoimmune process, we assessed relationships with clinical disease activity (16) . Our findings show that recirculating ACPA-expressing memory B cells generally persist despite treatment with conventional diseasemodifying antirheumatic drugs or TNF inhibition. Thus, the dysregulation of systemic autoimmunity in RA persists, even with remission of clinically relevant disease, which likely accounts for the failure of most treatment regimens to induce drug-free remission.
PATIENTS AND METHODS
Study design, human subjects, and sample procurement. All patients fulfilled the 2010 American College of Rheumatology/European League Against Rheumatism criteria for RA (17) Figure 1 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40053/abstract). Using a panel of avidin-coated microspheres and the same peptides/proteins, we also refined a multiplex bead-based array (Luminex), which has enhancements compared to methods described in a recent report (29) . Signal strength was quantified according to the median fluorescence intensity from .35 beads for each analyte per well. During assay development, an additive (SurModics) was included to limit the potential influence of RF in a sample. A recombinant human IgG1 antibody to citrullinated fibrinogen (clone 1F11; ModiQuest) was used as a positive control.
Synovial fluid mononuclear cell (SFMC) culture. Briefly, after joint aspiration, an aliquot of SF was cleared by centrifugation and then treated with hyaluronidase (20 units/ ml). Cells were recovered by Ficoll separation, washed, assessed for viability, and cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 10 mM HEPES, 0.1% 2-mercaptoethanol, penicillin/streptomycin/glutamine with or without CpG 2006, IL-21, and the CD40L-expressing feeder line, MS40L (30) .
Detection of antigen-specific or IgG-secreting cells (ISCs). To determine the frequencies of total IgG and antigen-specific IgG-secreting B cells, we adapted methodology for enzyme-linked immunospot (ELISpot) detection (31, 32) . Peripheral blood mononuclear cells (PBMCs), cultured with or without stimulants, were added at 2 3 10 5 /well to 96-well PVDF membrane plates (Millipore) coated with anti-human IgG Fc-specific F(ab 0 ) 2 (Jackson ImmunoResearch) to capture ISC products. To detect specificity, we added biotinylated CCP3, biotinylated cyclic glutamine-containing peptide 3 (CQP3), biotinylated tetanus toxoid (TT), or anti-human IgG antibody. To develop, we used streptavidin-HRP80 (RDI; Fitzgerald) and aminoethylcarbazole substrate. The enumeration of antigenspecific ISCs was normalized per 10 6 PBMCs. PBMC cultures. To assess the capacity for in vitro antibody secretion, PBMCs were isolated and cryopreserved, and later cultured at 10 6 cells per well for 6 days in 1 ml of RPMI complete media with 10% FBS, with or without CpG 2006 (6 mg/ml), IL-21 (50 ng/ml), and soluble CD40L (500 ng/ml), adapting previously reported conditions (31) . We used fluorescence-activated cell sorting to isolate four B cell subpopulations: CD271IgD-, CD271IgD1, CD27-IgD-, and CD27-IgD1 (see Supplementary Figure 2 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40053/abstract).
Statistical analysis. We assessed nonparametric pairedsample comparisons by Spearman's correlation using Prism software version 6.0e (GraphPad). P values less than 0.05 were considered significant.
RESULTS
Patient cohorts and the development of citrullinespecific immunoassays. Given our goal of investigating the contributions of circulating ACPA-specific B lymphocytes to RA pathogenesis, we first assembled cohorts of well-characterized patients. A cross-sectional cohort was established at New York University that included patients with new-onset RA and patients with established RA (Supplementary Table 1 ). Assays for IgG CCP3 demonstrated nearly complete concordance with the IgG CCP2 results obtained at enrollment (data not shown).
Development of a bead-based multiplex ACPA assay. To evaluate patterns of antibody reactivity with citrulline-containing proteins and autocyclizing synthetic peptides, we first independently evaluated reactivity by ELISA (Supplementary Figure 1) . These same peptides and proteins were then adapted to a multiplex bead-based array using a panel of avidin-coated microspheres, and we found significant correlations between results obtained with ELISA and our custom bead-based multiplex assays (see Supplementary Figure 3 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.40053/abstract).
To better assess the limits of detection, we evaluated the binding reactivity pattern of a recombinant human antibody to citrullinated fibrinogen, 1F11. This IgG1 antibody demonstrated a dose-dependent hierarchy of reactivity with a range of citrulline-containing antigenic ligands; with the most active antigenic ligands, reactivity was detectable at 0.1 ng/ml (data not shown).
With this multiplex assay, we characterized the circulating autoantibody fine specificity of sera from seropositive and seronegative RA patients ( Figure 1a ). The strongest IgG binding reactivity was generally with the CCP3 peptide, while only infrequent and, at best, weak reactivity was observed for the CQP3 peptide (which contains the neutral side chain of glutamine residues instead of charged arginine residues). Otherwise, RA patient sera displayed great heterogeneity in the fine specificities of the ACPAs when tested with a range of citrulline-containing antigens (Figures 1a and b) .
We also evaluated ACPA responses in the sera of RA patients who had received different treatment regimens (i.e., patient groups receiving oral MTX and/or a TNF inhibitor [TNFi]). We observed no major differences between these groups with respect to ACPA fine binding specificity, qualitatively or quantitatively, although we again found that seropositive RA patients were highly heterogeneous with respect to their IgG ACPA epitope specificity profiles (Figure 1b ). Samples from seronegative RA patients, as defined by CCP2 and CCP3 assays, were generally nonreactive with other citrulline-containing antigens, since our multiplex assay detected infrequent (0-4%) recognition, as assessed by IgG binding of Citpeptides/proteins, and then with only weak reactivity (Figure 1) , which is consistent with prior findings (33, 34) .
To further evaluate the clinical specificity of our assay, we tested sera from healthy subjects and patients with other rheumatic diseases, including osteoarthritis, systemic lupus erythematosus, psoriatic arthritis, and Sj€ ogren's syndrome (see Supplementary Table 3 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40053/abstract).
Our findings confirmed that the detection of IgG anticitrulline antigen reactivity with our assay was highly specific for patients with RA, since among these 87 disease-specific controls, we found that IgG reactivity with the CCP3 peptide or other citrullinated antigens was distinctly uncommon.
Specificity and frequency of disease-associated autoreactive B cells at the site of disease. To evaluate ACPAs produced at the site of disease, we assessed the capacity of our multiplex assay to detect ACPAs in SF samples from 2 seropositive RA patients. Substantial levels of CCP31 IgG were present, while no reactivity with the CQP3 control ligand was seen (Figure 2 ). Despite similar levels of CCP3 reactivity in these 2 SF samples, there were notable differences in the detection of IgG ACPA fine binding specificities with the other citrulline-containing peptides in the assay. , and SF mononuclear cell (SFMC) culture supernatant epitope reactivity patterns mirror those in autologous SF. SF was obtained from 2 RA patients, and SFMCs were isolated. SFMCs (1,000 or 10,000 per well) were cultured for 12 days with or without 3,000 MS40L cells/well and CpG 2006 and interleukin-21 (stim). Culture supernatants were analyzed using an enzyme-linked immunosorbent assay (ELISA) to detect IgG anti-CCP3, followed by a multiplex assay for epitope specificity of all positive and some negative wells. SF was tested at 1:100 and 1:1,000 dilutions by ELISA and multiplex assay. "Fresh" indicates directly ex vivo-cultured cells, and "cryo" indicates previously cryopreserved, thawed cells. RU 5 relative units (see Figure 1 for other definitions).
These SF mononuclear cell (SFMC) samples contained a substantial representation of lymphocytes with the surface phenotype of switched-memory B cells (data not shown). SFMCs were cultured in media supplemented with IL-21/CpG 2006, in the presence of the MS40L feeder cell line that enables in vitro clonal expansion of preactivated B cells (30) , which also induced 20-fold higher total IgG levels compared to unstimulated cultures (data not shown). IgG ACPAs were commonly detected in wells with 10,000 SFMCs, but were infrequent at 1,000 SFMCs/well, and never detected at 100 SFMCs/well. In each well, IgG ACPA fine specificity was heterogeneous, with the most common secreted ACPA epitope reactivities reiterating the same immunodominant ACPA specificities found in SF (Figure 2 ). While these studies document the high frequency of ACPA-expressing B cells at the site of disease, blood samples from these particular donors were, unfortunately, not available for comparison.
Detection of circulating antigen-specific peripheral B cells by ELISpot assay. To investigate the representation of circulating autoreactive B cells, we adapted ELISpot methods to evaluate the representation of ACPAexpressing B cells capable of constitutive ex vivo secretion (i.e., plasma cells/blasts) and B cells that required in vitro stimulation for IgG ACPA production (i.e., memory B cells) (31, 32) . Without in vitro stimulation, we detected only a very low frequency of spontaneous total ISCs (range 200-321/10 6 PBMCs), and by this method, we detected neither ACPA reactivity nor other TT-specific antibodies (data not shown). In stimulated PBMCs from seropositive RA patients, we found CCP3-reactive IgG spots in a mean 6 SEM of 41.3 6 0.5 ISCs/10 6 PBMCs (range 0-205), representing 0.13% of all ISCs (Figure 3a) . Only background levels were detected with the control peptide CQP3 (mean 6 SEM 1.9 6 0.6 ISCs/10 6 PBMCs). In contrast, for seronegative RA patients and healthy adults, CCP3 and CQP3 ISCs were below the limit of detection. These results confirmed that only RA patients have disease-specific circulating B cells capable of secreting IgG ACPAs.
As an internal control, we found that almost all RA patients and healthy subjects had detectable circulating IgG-expressing memory B cells reactive with the control bacterial antigen TT from the preventative vaccine that has been given to almost every adult. RA patients had a mean 6 SEM of 71.1 6 2.6 IgG anti-TT ISCs (range 0-205) and healthy adults had 65.4 6 1.2 anti-TT ISCs/10 6 PBMCs (range 0-220) (Figure 3a) , with no significant difference between the 2 groups. Notably, these experiments showed that the frequencies of recirculating anti-TT memory B cells overlap with the frequencies of ACPA-specific B cells in seropositive RA patients. Although these ELISpot assays were informative, we sought to develop a more efficient means of illuminating the broader range of fine binding autospecificities expressed by peripheral B cells in a donor. , and seropositive RA patients (n 5 33) were isolated and cultured with or without stimulation (stim), adapting previously described conditions (31) . Culture supernatants were assayed for antibody content by multiplex antigen bead assay using anti-human IgG (Fc-specific) R-phycoerythrin (eBioscience). Data are presented as the MFI. See Figure 1 for other definitions.
ACPA production by PBMCs from RA patients. To investigate the fine binding specificity of circulating citrulline antigen-reactive B cells, the PBMC culture conditions described above were used to induce B cell differentiation and antibody production, which we evaluated by multiplex bead array. Indeed, without stimulation, we detected only low levels of IgG (mean 0.16 mg/ml [range 0.01-0.56 mg/ml]), while with 6 days of stimulation, IgG levels were greatly increased (mean 7.65 mg/ml [range 1.85-20.95 mg/ml]). Based on IgG CCP3 reactivity, ACPAs were found in 15 of 33 supernatants (45.5%) from stimulated seropositive RA PBMCs (Figure 3b ). In general, wells that contained IgG anti-CCP3 antibodies also displayed a range of reactivities for other citrullinecontaining epitopes (but not arginine-containing analogs) that greatly varied between different RA donors. Taken together with the ELISpot results described above, these findings confirmed that seropositive RA patients commonly have circulating citrulline epitope-specific B cells.
Overall, IgG ACPAs were only detected in cultures of PBMCs from seropositive RA patients, and in most cases, only after 4-6 days of in vitro stimulation. ACPAs were infrequently detected in wells with unstimulated cells (i.e., 7 of 29 [24.1%] of seropositive RA patients) (Figure 3b) . Furthermore, the autoreactive blood B cell clones in different donors appeared to vary broadly by fine specificity for citrulline-containing self-antigen variants. These findings support the notion that RA patients have quiescent switched-memory B cells that can express ACPAs in their blood, while circulating constitutively IgG-secreting cells (i.e., plasma cells/plasmablasts) are much less commonly detected.
The relationship between the fine specificity of serum ACPAs and of the stimulated circulating ACPAexpressing memory B cells within the PBMCs was evaluated. Intriguingly, we found significant correlations between the serum IgG reactivities and in vitro secreted autoantibodies to CCP3 (P , 0.0001), Cit-filaggrin cfc6 (P 5 0.0001), and 7 other citrullinated antigens that were tested (see Supplementary Figure 4 , available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40053/abstract). Correlations for serum and in vitro-produced anti-TT antibody responses were also observed (P 5 0.03). These results strongly support the notion that there is a connection between epitope-specific ACPAs in serum and the fine specificities of circulating autoreactive B cells. However, clinical disease activity, based on the Disease Activity Score in 28 joints (DAS28) (35), correlated with neither the level nor the ACPA specificity in serum or supernatant (data not shown).
Evaluation of sorted peripheral blood B cells by multiplex assay. To directly determine which B cell subsets in the peripheral blood are the source of RA disease-associated ACPAs, we used flow cytometry to isolate CD3-CD14-CD191 B cells from PBMCs into 4 subpopulations: CD271IgD-cells, CD271IgD1 cells, CD27-IgD-cells, and CD27-IgD1 cells. The MS40L 
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cell line was then used for in vitro expansion of each sorted B cell subset of defined surface phenotype (30) . Sorted B cell subsets from 10 RA patients and 5 healthy individuals (see Supplementary Figure 2 for strategy) were separately cultured at 50 viable B cells per well. In a multiplex assay and confirmed by ELISA, only low or undetectable IgG levels were present after 0-2 days of in vitro culture, and ACPA reactivity was not detectable. Following culture of switched-memory B cells with stimulants for 12 days, we detected 10-fold greater levels of total IgG (mean 6 SD 3.2 6 2.4 mg/ml) than was associated with any other defined B cell subset. Cultured switched-memory B cells (CD271IgD-) most consistently produced high levels of IgG ACPAs. Otherwise, ACPAs were only infrequently detected in wells from "double-negative" B cells (CD27-IgD-). Other sorted subsets had no detectable ACPA activity (data not shown), since IgG ACPAs were never detected among preswitched-memory B cells (CD271IgD1) or naive/transitional B cells (CD27-IgD1).
Overall, these data document that IgG ACPAs primarily derive from switched-memory B cells (i.e., ACPA-expressing memory B cells) in the circulation of RA patients (Table 1) . Moreover, ACPA-expressing memory B cells were detected in the circulation of seropositive RA patients in both treatment groups tested (MTX or TNFi), with detection most frequently based on reactivity with the CCP3 ligand, while there was much greater heterogeneity with other individual citrullinecontaining peptides, but neither had detectable reactivity with B cells from seronegative RA patients or unaffected control subjects. We also surveyed for IgM autoantibodies, but every case of IgM reactivity with citrulline-containing ligands was associated with high polyreactivity with other antigens as well (data not shown), and therefore, no truly monospecific IgM ACPAs were detected.
Correlation of the burden of circulating ACPAexpressing B cells with serum levels of ACPAs. Based on evidence that seropositive RA patients commonly have circulating B cells that are capable of secreting IgG ACPAs, we wondered whether there was a relationship between the levels of these autoantibody-expressing memory B cells and their serum IgG ACPA levels. We therefore performed surveys on samples from a cross-sectional study of RA patients.
Overall, we found ACPA secretion in a mean of 1.4% of wells containing 50 viable switched-memory B cells (CD191CD271IgD-) (range 0-7.7%), while IgG ACPAexpressing B cells were never detected in healthy donors ( Table 1) . Considering the number of B cells that were tested, we estimated that ACPA reactivity was expressed by a mean 6 SD of 0.03 6 0.04% of switched-memory B cells in a seropositive RA patient (range 0-0.15%). Notably, we found a significant direct correlation between the proportion of wells with detectable IgG ACPAs and serum levels of IgG anti-CCP3 (Spearman's correlation r 5 0.57, P 5 0.003) (Figure 4a ). In general, ACPA-expressing B cells in individual wells exhibited great heterogeneity in their recognition of multiple autoantigenic determinants (Figure 4b ). Taken together, the data indicate that there is a biologic link between the frequencies of recirculating anticitrulline memory B cells and serum ACPA levels.
Lack of correlation of levels of circulating ACPA-expressing B cells with disease activity. Over the past 2 decades, there have been remarkable advances in the efficacy of treatment regimens, and in our capacity to accurately gauge overall disease activity in individual RA patients. Neither total blood levels of memory B cells nor IgG CCP3 antibody levels correlated with disease activity (data not shown). We therefore next sought to determine whether we could find relationships between RA clinical disease activity and levels of recirculating citrulline antigen-reactive memory B cells. Our crosssectional studies were performed on patients who displayed a wide range of serum IgG anti-CCP3 levels, and based on the DAS28 (36), disease activity ranged from high (DAS28 .5.1) in some patients to clinical remission (DAS28 ,2.6) in others. ACPA switched-memory B cells were found in the majority of seropositive RA patients (16 of 24 [66.7%]) (Figures 4 and 5 ). Yet, from quantitation of the frequency of wells with detectable ACPAs, we found only a nonsignificant trend toward a higher frequency of ACPA-expressing blood memory B cells in patients with higher DAS28 scores ( Figure 5 ). Further analyses in subsets of patients who received treatment with either methotrexate (MTX) or a biologic agent (TNFi) also failed to show a significant correlation. Most importantly, ACPA-expressing memory B cells were detected in most seropositive RA patients in clinical remission (8 of 14) , based on DAS28 scores of ,2.6 ( Figure 5 ).
In summary, treatment with standard of care regimens, while sufficient to reduce disease activity and, in some patients, to attain clinical remission, was not sufficient to eliminate ACPA-expressing memory B cells from the peripheral circulation, regardless of the DAS28 score ( Figure 5 ). A subset of RA patients had very high frequencies of circulating ACPA-expressing memory B cells, with a variety of ACPA epitope reactivity patterns in individual patients (Figure 4b ). Serum IgG CCP3 was also detected in the patient subsets with high, moderate, and low disease activity, as well as those in remission according to the DAS28, although this association was not significant (data not shown). Taken together, our results suggest that the presence of a high burden of circulating ACPA-expressing memory B cells may persist despite seemingly effective therapeutic interventions and is not reflected by standard measures of disease activity.
DISCUSSION
We found that seropositive RA patients, but not seronegative RA patients or healthy adults, have substantial levels of circulating anticitrullinated epitope-specific B Figure 5 . High burdens of circulating anti-citrullinated protein antibody (ACPA) switched-memory B cells (mBc) can be detected in the circulation of treated rheumatoid arthritis (RA) patients, including those whose disease is in clinical remission. For samples from patients with seropositive RA who were receiving tumor necrosis factor inhibitor (TNFi) therapy (n 5 12) or methotrexate (MTX; n 5 12), ACPApositive switched-memory B cells (per 10,000 switched-memory B cells cultured) were quantified as described in Figure 4 , plotted against the Disease Activity Score in 28 joints (DAS28), and analyzed by Spearman's correlation. The DAS28 using the C-reactive protein level (DAS28-CRP) was used in 21 patients, and the DAS28 using the erythrocyte sedimentation rate (DAS28-ESR) was used in 3 patients for whom CRP data were not available. Levels of ACPA-expressing switched-memory B cells did not correlate significantly with DAS28 scores. Results of correlation analyses with DAS28-CRP and DAS28cells, at frequencies akin to those for an antigen-specific protective B cell response. Circulating RA-associated ACPA-expressing B cells were predominantly switchedmemory (i.e., CD271IgD-) B cells (37-39) that do not spontaneously secrete ACPAs without in vitro activation. These B cells displayed a range of binding autospecificities for different citrullinated epitopes and were also crossreactive with the synthetic CCP3 peptide widely used to confirm the clinical diagnosis of RA, while they did not recognize native arginine-containing self-protein/peptide analogs.
Our surveys of a cross-sectional cohort of adult RA patients also revealed that the frequency of activatable citrullinated antigen-reactive B cells in a subject was directly proportional to serum IgG ACPA levels. While the range of IgG ACPA specificities expressed varied greatly between individual patients, for an individual RA patient the serum ACPA binding reactivity pattern was very similar to that induced by in vitro stimulation of disease-associated memory B cells. Whereas it has been argued that serum autoantibodies may be primarily produced by antibodysecreting B lineage cells that infiltrate affected synovial linings (20, 40) and/or the bone marrow (41), our findings suggest that the same clonal sets may be represented among the memory B cells in the bloodstream.
Progressive advances in our understanding of RA pathogenesis have led to the introduction of therapeutic agents that often provide high-hurdle clinical benefits, and biopsy/rebiopsy studies have shown this is generally paralleled by resolution of the pathogenic lymphocytic and myeloid synovial infiltrates in affected joints (42) (43) (44) . Yet despite these therapeutic advancements, such treatments are generally associated with only modest decreases in circulating IgM-RF or IgG ACPA/CCP, and very rarely do these serologic disease markers become undetectable.
In this study, we demonstrated that therapeutic interventions (MTX and/or TNFi) did not dependably abolish the recirculating autoantigen-targeted memory B cells that reflect the disease-associated defect in B cell immunologic tolerance, even in patients who attained clinical remission. Our findings therefore confirm that, despite the capacity of TNF inhibition to apparently disengage autoreactive B cells from the inflammatory destructive effector pathways in the rheumatoid synovial apparently disease process, these treatments do not appear to substantially impact the underlying pathogenic autoimmunity (as recently discussed [15] ).
Our integrated technical approach provided insights that complement other cutting-edge methods for the isolation and characterization of individual B cells in the RA autoimmune response. Recombinant monoclonal antibodies have been recovered and expressed from single synovium-infiltrating B cells, and RA B cell receptor repertoire studies have also provided the molecular characterization of ACPA binding specificity, B cell clonal relatedness, and immunogenetic origins (39, 45) . Tetramer technology for flow cytometric sorting has also been adapted for the study of autoantigen-specific B cells from RA patients (39) . While these approaches provide important perspectives, single B cell analyses enable detailed examinations of individual antigen-reactive lymphocytes (akin to the in-depth study of "individual trees"), while the latter approaches provide broad surveys of disease-associated B cell lineage "forests." Our approach provided an informative middle ground since it was designed to quantitate memory B cells and also elucidate autoantibody fine specificity and cross-reactivity in groups of patients. Our approach may require larger blood samples to derive more-accurate frequencies when in vivo levels of ACPA-expressing B cells among peripheral B cells are low. In the future, we would like to apply our now validated methods to longitudinal studies of individuals before and after starting a new agent.
Our investigations have provided direct evidence that memory B cells are not eradicated in peripheral blood following therapeutic attainment of clinical remission. Therefore, the regimens that we examined are insufficient for induction of long-term immune remission. In fact, patients with high serum IgG anti-CCP3 levels were significantly more likely to have high frequencies of ACPA-expressing switched-memory B cells, suggesting there are likely ongoing roles for these cells in the production of serum ACPAs. Our findings also suggest that serum ACPA levels are closely intertwined with the persistence of circulating ACPA-expressing memory B cells. We therefore wonder about the relationship between memory B cells and long-lived plasma cells, as our findings are consistent with a model in which memory B cells are required to replenish ACPA-secreting plasma cells in the bone marrow and potentially at other sites.
The contributions of B cells to RA pathogenesis have been best documented by the clinical efficacy of rituximab, the prototypical anti-CD20 antibody, which induces efficient eradication of B cells from the blood. However, the impact at other sites may not be accurately reflected in the bloodstream levels. In treated RA patients with clinical benefits, when in vivo therapeutic anti-CD20 levels later wane, the return of detectable levels of blood B cells is often associated with an overall reduction in the levels of different CD271 B cell subsets that can persist for years (46) . Yet, to the best of our knowledge, the proportions of these posttreatment recovery memory B cells linked to host immune defenses versus disease-associated autoimmunity have not been investigated.
In conclusion, our results highlight the fact that commonly used treatment regimens are deficient in affecting the underlying pathologic autoimmune disease process. These findings therefore help to rationalize the outcome of 2 large trials in which cessation of therapy in RA patients in clinical remission led to relapse in the great majority of RA patients within the first year (47) (48) (49) . Indeed, these regimens fail to provide an effective cure for RA because they do not have the capacity to target the reservoirs of pathogenic autoreactive B cells (as well as T cells).
We therefore propose that the next phase in the development of RA therapy should have a goal of deleting pathologic memory cells and reversing the defect in immune tolerance. Progress toward this goal will require the adoption of a new standard for differentiating clinical remission from true immune remission, which includes an assessment of cellular autoimmune players that will otherwise be responsible for disease reactivation and clinical relapse. Our technical approach for assessing the autoimmune B cell burden in RA patients may therefore provide this essential tool for assessing the capacity of treatment regimens to target and eliminate disease-specific autoimmunity, as well as for making better and more informed treatment decisions in daily clinical practice.
